Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

WALTHAM, Mass., July 9, 2025 /PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today ...

Sironax retains the right to continue developing selected therapeutic assets using the platform. "This partnership combines Novartis's global expertise in neuroscience with Sironax's high-quality ...

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...

Sironax retains the right to continue developing selected therapeutic assets using the platform. “This partnership combines Novartis’s global expertise in neuroscience with Sironax’s high-quality ...

WALTHAM, Mass., July 9, 2025 /PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today ...

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic AssetsDisclaimer The content, including but not limited to any ...

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Eledon, Iambic, Jasper, Lupin, Novartis, Qanatpharma, Revolution Medicines, Sernova, Sironax, ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...